MP1032 Treatment in Patients With Moderate to Severe COVID-19

Completed · Phase 2 · Has a placebo group

Conditions studied: COVID-19

In brief

The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).

Key facts

Study ID
NCT04932941
Run by
MetrioPharm AG
People needed
132
Starts
2021-10-19
Expected to finish
2022-09-05
Last updated by the study team
2023-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.